Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience
There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable n...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/69973 |
| _version_ | 1848762182370590720 |
|---|---|
| author | Ward, Natalie Pang, J. Ryan, J. Watts, G. |
| author_facet | Ward, Natalie Pang, J. Ryan, J. Watts, G. |
| author_sort | Ward, Natalie |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C–lowering therapy in statin-intolerant patients, with evidence from our own clinical practices. |
| first_indexed | 2025-11-14T10:43:30Z |
| format | Journal Article |
| id | curtin-20.500.11937-69973 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:43:30Z |
| publishDate | 2018 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-699732018-10-15T03:26:56Z Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience Ward, Natalie Pang, J. Ryan, J. Watts, G. There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C–lowering therapy in statin-intolerant patients, with evidence from our own clinical practices. 2018 Journal Article http://hdl.handle.net/20.500.11937/69973 10.1002/clc.22862 restricted |
| spellingShingle | Ward, Natalie Pang, J. Ryan, J. Watts, G. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title_full | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title_fullStr | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title_full_unstemmed | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title_short | Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| title_sort | nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience |
| url | http://hdl.handle.net/20.500.11937/69973 |